Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations

Table 3 Autoantibody titers in chronic hepatitis B compared with chronic hepatitis C, autoimmune hepatitis, primary biliary cirrhosis, and healthy controls

	CHB (n = 325)		CHC (n = 71)		AIH (n = 11)		PBC (n = 71)		HC (n = 60)
	Pos. cases	Mean rank1	Pos. cases	Mean rank	Pos. cases	Mean rank	Pos. cases	Mean rank	Pos. cases	Mean rank
ANA	76	66.79a	13	50	6	97.5	47	83.57	2	100.5
SMA	10	6.20	2	8	0	-	0	-	0	-
AMA-M2	22	23.61d	2	11	1	11.0	60	51.71	0	-
Anti-BPO	23	22.85d	1	10.5	1	10.5	60	51.81	0	-
Anti-Sp100	8	8.44	0	-	1	5.0	11	12.50	0	-
Anti-PML	36	29.54b	0	-	3	19.0	30	43.15	0	-
Anti-gp210	41	28.49d	0	-	2	26.75	35	53.13	0	-
Anti-LKM-1	2	1.50	1	4	1	4.0	0	-	0	-
Anti-LC-1	10	9.45	1	7	3	10.17	3	7.00	0	-
Anti-SLA/LP	7	6.00	0	-	3	8.17	3	8.17	0	-
Anti-Ro52	91	68.89b	10	50.9	4	94.25	36	91.89	4	30.5

¹Kruskal-Wallis H test;

^aP < 0.05, Mann-Whitney U test vs the autoantibody titers with PBC;

^bP < 0.01, Mann-Whitney U test vs the autoantibody titers with PBC;

^dP < 0.01 Mann-Whitney U test vs the autoantibody titers with PBC; “-”: Not indicated; P < 0.05 was considered significant. CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; HC: Health controls; ANA: Anti-nuclear antibodies; AMA: Anti-mitochondrial antibodies; SMA: Smooth-muscle antibodies; anti-PML: Anti-promyelocytic leukemia protein; anti-LKM-1: Anti-liver kidney microsome type 1; anti-LC-1: Anti-liver cytosolic antigen type 1; anti-SLA/LP: Anti-soluble liver antigen/liver pancreas; IFA: Indirect immunofluorescence assay; LIA: Line immunoassay.